These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

90 related articles for article (PubMed ID: 23769978)

  • 1. The background, discovery and clinical development of BCR-ABL inhibitors.
    Lambert GK; Duhme-Klair AK; Morgan T; Ramjee MK
    Drug Discov Today; 2013 Oct; 18(19-20):992-1000. PubMed ID: 23769978
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Mechanisms of resistance to BCR-ABL and other kinase inhibitors.
    Lamontanara AJ; Gencer EB; Kuzyk O; Hantschel O
    Biochim Biophys Acta; 2013 Jul; 1834(7):1449-59. PubMed ID: 23277196
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Design and synthesis of 3-substituted benzamide derivatives as Bcr-Abl kinase inhibitors.
    Asaki T; Sugiyama Y; Hamamoto T; Higashioka M; Umehara M; Naito H; Niwa T
    Bioorg Med Chem Lett; 2006 Mar; 16(5):1421-5. PubMed ID: 16332440
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Second generation inhibitors of BCR-ABL for the treatment of imatinib-resistant chronic myeloid leukaemia.
    Weisberg E; Manley PW; Cowan-Jacob SW; Hochhaus A; Griffin JD
    Nat Rev Cancer; 2007 May; 7(5):345-56. PubMed ID: 17457302
    [TBL] [Abstract][Full Text] [Related]  

  • 5. New insights into small-molecule inhibitors of Bcr-Abl.
    Schenone S; Bruno O; Radi M; Botta M
    Med Res Rev; 2011 Jan; 31(1):1-41. PubMed ID: 19714578
    [TBL] [Abstract][Full Text] [Related]  

  • 6. HS-438, a new inhibitor of imatinib-resistant BCR-ABL T315I mutation in chronic myeloid leukemia.
    Yun SM; Jung KH; Kim SJ; Fang Z; Son MK; Yan HH; Lee H; Kim J; Shin S; Hong S; Hong SS
    Cancer Lett; 2014 Jun; 348(1-2):50-60. PubMed ID: 24657654
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Allosteric inhibitors of Bcr-abl-dependent cell proliferation.
    Adrián FJ; Ding Q; Sim T; Velentza A; Sloan C; Liu Y; Zhang G; Hur W; Ding S; Manley P; Mestan J; Fabbro D; Gray NS
    Nat Chem Biol; 2006 Feb; 2(2):95-102. PubMed ID: 16415863
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Structural mechanism of the Pan-BCR-ABL inhibitor ponatinib (AP24534): lessons for overcoming kinase inhibitor resistance.
    Zhou T; Commodore L; Huang WS; Wang Y; Thomas M; Keats J; Xu Q; Rivera VM; Shakespeare WC; Clackson T; Dalgarno DC; Zhu X
    Chem Biol Drug Des; 2011 Jan; 77(1):1-11. PubMed ID: 21118377
    [TBL] [Abstract][Full Text] [Related]  

  • 9. BCR-ABL- and Ras-independent activation of Raf as a novel mechanism of Imatinib resistance in CML.
    Hentschel J; Rubio I; Eberhart M; Hipler C; Schiefner J; Schubert K; Loncarevic IF; Wittig U; Baniahmad A; von Eggeling F
    Int J Oncol; 2011 Sep; 39(3):585-91. PubMed ID: 21637917
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Structural analysis of DFG-in and DFG-out dual Src-Abl inhibitors sharing a common vinyl purine template.
    Zhou T; Commodore L; Huang WS; Wang Y; Sawyer TK; Shakespeare WC; Clackson T; Zhu X; Dalgarno DC
    Chem Biol Drug Des; 2010 Jan; 75(1):18-28. PubMed ID: 19895503
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Apoptosis in chronic myeloid leukemia cells transiently treated with imatinib or dasatinib is caused by residual BCR-ABL kinase inhibition.
    Simara P; Stejskal S; Koutna I; Potesil D; Tesarova L; Potesilova M; Zdrahal Z; Mayer J
    Am J Hematol; 2013 May; 88(5):385-93. PubMed ID: 23420553
    [TBL] [Abstract][Full Text] [Related]  

  • 12. BCR-ABL tyrosine kinase inhibitors in the treatment of Philadelphia chromosome positive chronic myeloid leukemia: a review.
    An X; Tiwari AK; Sun Y; Ding PR; Ashby CR; Chen ZS
    Leuk Res; 2010 Oct; 34(10):1255-68. PubMed ID: 20537386
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Gab2 signaling in chronic myeloid leukemia cells confers resistance to multiple Bcr-Abl inhibitors.
    Wöhrle FU; Halbach S; Aumann K; Schwemmers S; Braun S; Auberger P; Schramek D; Penninger JM; Laßmann S; Werner M; Waller CF; Pahl HL; Zeiser R; Daly RJ; Brummer T
    Leukemia; 2013 Jan; 27(1):118-29. PubMed ID: 22858987
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Electrochemical evaluation of Abelson tyrosine-protein kinase 1 activity and inhibition by imatinib mesylate and danusertib.
    Diculescu VC; Enache TA
    Anal Chim Acta; 2014 Oct; 845():23-9. PubMed ID: 25201268
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Overriding imatinib resistance with a novel ABL kinase inhibitor.
    Shah NP; Tran C; Lee FY; Chen P; Norris D; Sawyers CL
    Science; 2004 Jul; 305(5682):399-401. PubMed ID: 15256671
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Different target range and cytotoxic specificity of adaphostin and 17-allylamino-17-demethoxygeldanamycin in imatinib-resistant and sensitive cell lines.
    Barnes DJ; De S; van Hensbergen P; Moravcsik E; Melo JV
    Leukemia; 2007 Mar; 21(3):421-6. PubMed ID: 17252018
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Discovery of novel Bcr-Abl inhibitors targeting myristoyl pocket and ATP site.
    Dong J; Lu W; Pan X; Su P; Shi Y; Wang J; Zhang J
    Bioorg Med Chem; 2014 Dec; 22(24):6876-84. PubMed ID: 25464886
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Analysis of ABL kinase domain mutations conferring resistance to tyrosine kinase inhibitors in chronic myeloid leukemia cases from India.
    Bagadi S; Saikia T; Pany A; Das B
    Clin Lab; 2011; 57(7-8):619-23. PubMed ID: 21888027
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Characterization of compound 584, an Abl kinase inhibitor with lasting effects.
    Puttini M; Redaelli S; Moretti L; Brussolo S; Gunby RH; Mologni L; Marchesi E; Cleris L; Donella-Deana A; Drueckes P; Sala E; Lucchini V; Kubbutat M; Formelli F; Zambon A; Scapozza L; Gambacorti-Passerini C
    Haematologica; 2008 May; 93(5):653-61. PubMed ID: 18367480
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Single-cell analysis of K562 cells: an imatinib-resistant subpopulation is adherent and has upregulated expression of BCR-ABL mRNA and protein.
    Karimiani EG; Marriage F; Merritt AJ; Burthem J; Byers RJ; Day PJ
    Exp Hematol; 2014 Mar; 42(3):183-191.e5. PubMed ID: 24269846
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.